Dapagliflozin-3-O-β-D-glucuronide

Dapagliflozin-3-O-β-D-glucuronide (BMS-801576) is the metabolite of Dapagliflozin (HY-10450), and is formed in the liver and kidney by uridine diphosphate glucuronosyltransferase-1A9 (UGT1A9) . Dapagliflozin is a selective inhibitor for SGLT2, that can be used to improve glycemic control and attenuate type 2 diabetes[1].

Product Specifications

CAS Number

[1351438-75-9]

Product Name Alternative

BMS-801576

UNSPSC

12352005

Hazard Statement

H302

Target

Endogenous Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/dapagliflozin-3-o-β-d-glucuronide.html

Purity

99.0

Solubility

DMSO : 1 mg/mL (ultrasonic; warming)

Smiles

ClC1=C(CC2=CC=C(C=C2)OCC)C=C([C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@]4([C@@H]([C@H]([C@@H]([C@H](O4)C(O)=O)O)O)O)[H])O)C=C1

Molecular Formula

C27H33ClO12

Molecular Weight

585.00

Precautions

H302

References & Citations

[1]Kasichayanula S, et al., Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53 (1) :17-27.